Trials / Completed
CompletedNCT04400188
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
A Phase Ⅰb/Ⅱ Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of the combination of Fluzoparib (SHR-3162) and temozolomide with or without SHR-1316 in small cell lung cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib | Given PO |
| DRUG | temozolomide | Given PO |
| BIOLOGICAL | SHR-1316 | Given injection |
Timeline
- Start date
- 2020-06-11
- Primary completion
- 2022-01-15
- Completion
- 2022-01-15
- First posted
- 2020-05-22
- Last updated
- 2025-06-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04400188. Inclusion in this directory is not an endorsement.